Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.

dc.contributor.authorPeinado, Paola
dc.contributor.authorAndrades, Alvaro
dc.contributor.authorCuadros, Marta
dc.contributor.authorRodriguez, Maria Isabel
dc.contributor.authorCoira, Isabel F
dc.contributor.authorGarcia, Daniel J
dc.contributor.authorÁlvarez-Perez, Juan Carlos
dc.contributor.authorBaliñas-Gavira, Carlos
dc.contributor.authorArenas, Alberto M
dc.contributor.authorPatiño-Mercau, Juan Rodrigo
dc.contributor.authorSanjuan-Hidalgo, Juan
dc.contributor.authorRomero, Octavio A
dc.contributor.authorMontuenga, Luis M
dc.contributor.authorCarretero, Julian
dc.contributor.authorSanchez-Cespedes, Montserrat
dc.contributor.authorMedina, Pedro P
dc.date.accessioned2025-01-07T17:30:23Z
dc.date.available2025-01-07T17:30:23Z
dc.date.issued2020-12-10
dc.description.abstractMammalian SWI/SNF (SWitch/Sucrose Non-Fermentable) complexes are ATP-dependent chromatin remodelers whose subunits have emerged among the most frequently mutated genes in cancer. Studying SWI/SNF function in cancer cell line models has unveiled vulnerabilities in SWI/SNF-mutant tumors that can lead to the discovery of new therapeutic drugs. However, choosing an appropriate cancer cell line model for SWI/SNF functional studies can be challenging because SWI/SNF subunits are frequently altered in cancer by various mechanisms, including genetic alterations and post-transcriptional mechanisms. In this work, we combined genomic, transcriptomic, and proteomic approaches to study the mutational status and the expression levels of the SWI/SNF subunits in a panel of 38 lung adenocarcinoma (LUAD) cell lines. We found that the SWI/SNF complex was mutated in more than 76% of our LUAD cell lines and there was a high variability in the expression of the different SWI/SNF subunits. These results underline the importance of the SWI/SNF complex as a tumor suppressor in LUAD and the difficulties in defining altered and unaltered cell models for the SWI/SNF complex. These findings will assist researchers in choosing the most suitable cellular models for their studies of SWI/SNF to bring all of its potential to the development of novel therapeutic applications.
dc.identifier.doi10.3390/cancers12123712
dc.identifier.issn2072-6694
dc.identifier.pmcPMC7763689
dc.identifier.pmid33321963
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7763689/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/12/12/3712/pdf?version=1607654543
dc.identifier.urihttps://hdl.handle.net/10668/28417
dc.issue.number12
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationCentro Pfizer-Andalucía de Genómica e Investigación Oncológica (GENYO)
dc.organizationCentro Pfizer-Andalucía de Genómica e Investigación Oncológica (GENYO)
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectSWI/SNF complex
dc.subjectcell models
dc.subjectepigenetics
dc.subjectlung adenocarcinoma
dc.subjectlung cancer
dc.subjectmulti-omics
dc.titleComprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7763689.pdf
Size:
1.73 MB
Format:
Adobe Portable Document Format